The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
GDR - no sales of their gold standard test in over a year during a pandemic. Let that sink in. When the current excitement over an approval subsides get to hell out fast. Approvals - GDR has a bucket load of those but can't sell anything.
"Best thing is have a look at the Company's own presentation in Nov '21 on the failure to commercialise GENEDRIVE® 96 SARS COV-2 KIT"
I don't think any of these rampers have read anything about this company. That is why they just post rubbish about the share price. Once the share price starts to fall they will be gone. Don't be left holding the baby. Reality will set in and sales will be poor and the share price will crash again.
"https://www.sanderson-out.org/ 4.63% now signed up. SS must be getting a bit twitchy. Squeaky bum time..."
You need to be quick before SS conjures up another few billion shares and your 4.63% turns into 3%. Did you have to put a photo of that arrogant, greedy ,thieving little **** on your site, it makes me physically sick looking at him.
"Unless someone pulls a rabbit out of the hat soon, this could increase to 2bn shares with an mcap of £350M"
I think most would see an increase to 2bn shares as a great result if the finance was sorted.
"If I remember rightly, what is more impressive is that the testing saved two babies hearing.
now that is something worth investing in"
-----
For sure. Maybe there should be a greater urgency in getting this rolled out across the country and the world.
@RedRoy Having also suffered the SXX debacle I do not underestimate the difficulty in a small MC company obtaining huge debt/equity finance. The finance gurus there gambled on an all or nothing situation and spent what cash they had as they were confident the deal would come off. It didn't and the rest is history, well SXX certainly is. Maybe they have learned some lessons from that and are positioning themselves to raise more from placings if the financing cannot be finalized in the next few months. Probably a sensible position to take - I wish SXX had done the same
If it looked like the finance was going to be agreed in the next few months as planned then I am sure there would be no move to AIM needed. Looks like they can't get funding at this stage at least and will be needing to raise some funds on AIM market. It was always a big ask for a small 40 mill MC company to secure over 200 mill in debt and over 100 mill in equity investment.
"Nothing to be unknown, low cost, high margin, fingers crossed this be the only dilution?"
-----
Where are they going to get the other 100 million + from without dilution? There will be massive dilution whether it is through multiple placings on AIM or large investors wanting a big chunk for their money. We have seen the dilution for 5 million, I will not try to think about the dilution for 100 mill. I think we will see a period where the MC will increase but due to dilution the share price will not.
People selling at 130 are betting against BC being able to sell even a modest number of their machines. Someone posted an article about a US lab with 2 of these machines and they were very happy that they got an order in early or they would be on a waiting list for a few months. This one lab had 2, how many other labs have already been supplied? What does the waiting list tell you about demand? Is 100 of these machines a conservative estimate and what would that mean for a company with 80 mill MC.
I guess the real concern here is how much equity will be given to secure funding. The equity funding partners will be in the driving seat given the amount required.
If our tests are running on 100 automated machines which is fairly conservative -
100 X 2000 tests a day = 200000 X £10 per test = 2,000,000 per day
That is 60 million revenue per month or 360 million in next 6 months
The MC is only 80 million and we haven't even considered the other products. The hearing test alone could easily justify that MC.
Think they need a new CEO more than a Quality Assurance tech. From the job ad - "Earlier this year, we developed a novel Genedrive® 96 SARS-CoV-2 Kit using a novel Polymerase Chain Reaction (PCR) assay designed to detect active infection in COVID-19 patients for commercial sale to assist in the global fight to contain and defeat Covid-19 "
Don't think your contribution to the global fight to contain and defeat Covid-19 has been up to much in the last 6 months.
"no good whinging its Db's fault they are down... if this goes to 90p next week they will be lining up to Kiss his Ar S£"
Well the reality is total failure by DB to sell anything in a period of global pandemic and when no vaccine was ready. Months ago he was presenting a gold standard product and talking sales in June. He threw in statements like multi million contract very close as well while he paid himself and his mates a fortune and while the big boys converted and got out. If it goes to 90p next week it will still have been a massive failure so no ass kissing will be happening.
"You expect a company to say SOMETHING just to ease the mind of some PIs......hahaha good one. Just wait for news like a grown up."
No I expect them to sell the product they were talking up 7 months ago, the one they have spent nearly a year on and a lot of shareholder money, the one where they have had approval to sell for 6 months.
If Budd had any integrity he would resign in disgrace. He was talking up this product and bull****ting about sales in June and here we are 6 months later and sweet FA. Everyone knew this was a time limited opportunity and it has been totally wasted by this company while others have pushed ahead. Just way too slow for this market. There should be no rewards for failure, please just go.
Ok - it's a week since the last conversion - at £75k a week that's another 26 weeks to pay off the YA debt.
That's the 20th November........ this is a real albatross around the shares
And that assumes they don't go back for more
-----------
75k a week - so 10 weeks to pay for Sandersons salary. Someone got my post deleted before for suggesting that Sanderson is stealing shareholder money but if this 750k salary and 300k bonus cannot be justified it is the same as theft in my view. He has the option to come out of hiding to tell everyone of his achievements to justify this but chooses not too. Surely he should be shouting from the rooftops only the reality is that there are no achievements just failures.